ClinicalTrials.gg
Active, not recruitingNCT07663903Updated Sep 8, 2026

Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment

A Phase 3 interventional study of FRSW107 in Severe Hemophilia A, sponsored by Hangzhou Gensciences Biopharmaceutical Co., Ltd.. Active, not recruiting at 24 sites in China. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Hemophilia A with a site in China — 28 open to participants now, 39 under way, 19 of them phase 3. Hemophilia A · China.

Planned enrollment
33rd of 80
60 · median 54
Started
2026
with 8 others
Phase 3
41 of 93
9 open now
Primary completion
2027-02
later than 17 of 38 live
Registered
91st of 93
by date

Among the 93 studies in Hemophilia A with a site in China, this one is the 33rd largest by planned enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2026, is one of 41 in phase 3, reaches primary completion later than 17 of the 38 other live ones, and was the 91st registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

28 of the 93 studies in Hemophilia A with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Hemophilia A with a site in China, or all of them as a file.
02

Study summary

The indication for this product is to control bleeding in patients with hemophilia A (congenital deficiency of factor VIII).

The primary objective:

Evaluation of the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW107) as an on-demand treatment in previously treated patients with severe hemophilia A.

Secondary objectives:

Evaluation of the safety and immunogenicity of FRSW107 as an on-demand therapy in previously treated patients with severe hemophilia A.

Evaluate the on-demand treatment's PK profile of FRSW107 in previously treated patients with severe hemophilia A based on population pharmacokinetic (PopPK) methods ; preliminarily investigate the exposure-response (E-R) relationship of FRSW107 on-demand treatment in these patients if data permit.

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusive Criteria:

  1. Males aged 12 or younger to 65 years old.
  2. Patients clinically diagnosed with severe hemophilia A, i.e., those confirmed through screening or previous medical records: FⅧ Activity \< 1%.
  3. Previous records confirm receipt of any recombinant and/or blood-derived coagulation factor VIII products or cold precipitate products, with a treatment of ≥150 exposure days (EDs ≥150).
  4. The participants have fully understood and been informed of this study, signed the form, and voluntarily enrolled in the clinical trial. The trial participants and/or their guardians are capable of cooperating with the hemostatic treatment and have the ability to complete all study procedures.

Exclusion Criteria:

  1. Known or suspected allergy to the drug or its , including mouse or hamster proteins;
  2. or anaphylaxis after FⅧ or IgG2 injection in the past;
  3. FⅧ inhibitor positive (≥0.6 BU/mL) during the screening period, or have a history of FⅧ inhibitor positive in the past, or a family history of FⅧ inhibitor positive;
  4. Von Willebrand factor (vWF) antigen test results were lower than the lower limit of normal value;
  5. Severe anemia at the screening stage ( \< 60 g/L);
  6. count during screening period \< 100×109 /L;
  7. Abnormal liver function:

    . (ALT), or aspartate aminotransferase (AST) >3 times (ULN); or Serum total (TBIL) >1.5x ULN;

  8. Patients with abnormal renal function:

    (Ccr) \<50 ml/min (according to Cockcroft and Gault formula); or Serum creatinine (Cr) >1.5x ULN;

  9. People with active , that is, hepatitis C virus (HCV) antibody positive and HCV RNA positive; Or anti-treponema pallidum specific antibody (TPHA) positive; Or positive for antibodies against the (HIV);
  10. Patients with coagulation dysfunction other than hemophilia A;
  11. Have a medical condition that may increase the risk of bleeding;
  12. A history of drug or alcohol abuse;
  13. Have a known mental disorder that may affect trial compliance;
  14. Patients who have received transfusions of blood or blood components within 4 weeks prior to screening;
  15. Participants who had participated in other clinical trials within 1 month before screening;
  16. Use of any anticoagulant or antiplatelet drugs, off-label maximum dose of non-steroidal anti-inflammatory drugs (NSAID) within 7 days prior to screening; Or patients who need to be treated with anticoagulant or antiplatelet drugs or off-label maximum doses of SAID during clinical trials;
  17. Severe cardiovascular and cerebrovascular disease or major thromboembolic events, such as stroke, myocardial infarction, unstable angina, congestive heart failure ( [NYHA] grade ≥ III), and severe arrhythmias (including interphase > 480 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic ≥ 160 mmHg or diastolic ≥100 mmHg), deep vein thrombosis, etc.
  18. Study patients who had used emesezumab within 6 months prior to first administration of the drug;
  19. Patients who had used monoclonal antibody therapy, Fc fusion protein products (except FRSW107 and FRSW117), PEG products (except FRSW117), or intravenous immunoglobulin infusion within 3 months before the first administration of the investigational drug;
  20. Study patients who underwent major surgery within 3 months prior to initial drug administration (major surgery is defined in 6.2.3 Perioperative management);
  21. Study patients who have used FⅧ preparation of any standard half-life (e.g., Bycoch, Coproch, Biinidin, Renjie, NoL, Antaine, etc.) within 3 days or 5 half-lives prior to first administration of the drug (taking the elderly); Patients who have used any other extended half-life preparation FⅧ within 4 days or 5 half-lives prior to first dosing (for the elderly);
  22. Study patients with fever, severe active bacterial or viral infection, and allergies within 2 weeks before the first administration of the drug;
  23. Systemic immunomodulators (such as [> 10 mg/ day equivalent dose of prednisone], alpha-interferon, immunoglobulin, cyclophosphamide, cyclosporin, etc.) used within 14 days prior to the first administration of the study drug or planned during the study period were allowed to be inhaled, nasal spray, or topical corticosteroids;
  24. Those who had been vaccinated within 4 weeks prior to initial administration of the study drug; Or who plan to be vaccinated during PK blood collection (only for subjects in the PK subgroup);
  25. Plan to have a child or sperm donation during the entire trial period and within 3 months after the last dose, or do not want to use effective physical (such as condoms, diaphragms, Iuds, etc.);
  26. Have other serious medical conditions that the researchers said could not benefit from them
  27. Subjects deemed unsuitable by other investigators.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    On-demand Treatment.

    On-demand treatment (recommended range: 20-50 IU/kg)

    Drug: FRSW107

Interventions

  • Treatment for 6 months as needed.

06

What researchers measure

Primary outcomes

  1. The haemostatic effective rate

    The haemostatic effect of FRSW107 when used for treatment of bleeds, assessed on a four-point scale for haemostatic response (excellent, good, moderate and none) by counting excellent and good as success and moderate and none as failure.

    Time frame: 6 months

Secondary outcomes

  1. Number of infusions and IU/kg of FRSW107 needed for the treatment of bleeding episodes

    Time frame: 6 months

  2. FVIII activity during on-demand: activity recovery rate

    FVIII activity recovery rate on Day1's haemostatic therapy.

    Time frame: Visit1,Day1

  3. Hemophilia Joint Health Score (HJHS 2.1) during on-demand treatment

    total score and each subscale score of HJHS 2.1, as well as their changes over time.

    Time frame: 6 month

  4. incidence of lack of drug efficacy

    Lack of drug efficacy is defined as: during on-demand treatment, hemostatic efficacy is assessed as "ineffective" or "poor/no response" following two consecutive administrations within 72 hours for the same bleeding episode. incidence of lack of drug efficacy=number of lack of drug efficacy/number of evaluated treatment\*100%.

    Time frame: 6 months

  5. Occurrence of AEs and SAEs

    Time frame: 6 month

  6. Incidence rate of positive FVIII inhibitors

    A positive FⅧ inhibitor is defined as a Bethesda inhibitor titer ≥ 0.6 BU/mL. Incidence rate of positive FVIII inhibitors=number of positive FⅧ inhibitors participant / total number of trial participants \*100%.

    Time frame: 6 month

  7. Incidence rate of positive ADA, Incidence rate of positive anti-CHO antibody

    Incidence rate of positive ADA=number of positive ADA participant / total number of trial participants \*100% Incidence rate of positive anti-CHO antibody=number of positive anti-CHO antibody participant / total number of trial participants \*100%

    Time frame: 6 month

07

Study locations

24 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 10 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 23, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Jun 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07663903
Lead sponsor
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Apr 14, 2026
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Renchi Yang, PhD
study chair · Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FRSW107

Start the discussion